As a result, the ability of IL‐6 to increase the expression of NSCLC cells' AKR1C1/1C2 expression and its involvement in the establishment of drug resistance to Adriamycin and Cisplatin was discovered for the first time in this work. Here, IL6 is linked to non-small cell lung carcinoma.